MYPT1
, the targeting subunit of smooth muscle myosin phosphatase, is a substrate for the asparaginyl hydroxylase factor inhibiting hypoxia inducible factor (FIH)
Introduction
Factor inhibiting hypoxia inducible factor (FIH) is an asparaginyl hydroxylase that contributes to oxygen-dependent regulation of hypoxically-induced genes by hydroxylation of Hypoxia Inducible transcription Factor (HIF) [1, 2] . Hydroxylation of the HIF C-terminal transactivation domain (CAD) suppresses HIF activity by preventing recruitment of the p300/CBP transcriptional co-activators to HIF target genes [3, 4] .
Recently several novel substrates of FIH have been identified that are targeted for Asn hydroxylation within a protein:protein interaction motif known as the Ankyrin Repeat (AR) Domain (ARD). These experiments have demonstrated that Asn hydroxylation occurs at multiple sites within the ARDs of several proteins, including; IκBα, Notch1 -3, ASB4, Rabankyrin and RNaseL [5] [6] [7] [8] . Quantitative MS/MS analyses have demonstrated that the extent of hydroxylation may vary between sites in the same ARD, and is generally incomplete at any given site, at least in cells grown in the standard tissue culture conditions used in these experiments. However, despite the identification of multiple ARD substrates of FIH, functional insights into the role of ARD hydroxylation have so far been limited [5, 6] . Though effects of FIH have been reported on biological functions of some of these target proteins it is not yet clear how they relate to hydroxylation [7, 9] .
ARDs contain variable numbers of ARs which consist of paired anti-parallel α-helices that stack upon one another to form a protein interaction surface [10] . Although hydroxylation of the Notch1 ARD promotes the formation of an intra-repeat hydrogen bond postulated to enhance structural stability, it does not alter the classical ARD conformation [6] . The clearest biological action of an FIH-mediated ARD hydroxylation defined to date is the crosscompetition between Notch 1 and HIF-CAD for Asn hydroxylation. Thus expression of the ARD of Notch1 competitively inhibits FIH-mediated HIF-CAD Asn hydroxylation, resulting in enhanced HIF-CAD activity [6] .
Although yeast 2-hybrid and proteomic screens have identified only a relatively small number of ARD substrates of FIH [5, 6 ] the human genome encodes over 300 ARD proteins, most of which contain consensus motifs for FIH-mediated hydroxylation (SMART database [11] ). This raises important questions as to whether hydroxylation occurs on other ARD proteins and if so, to what extent, what roles hydroxylation might play in hypoxia signalling, and what the implications are for cross-competition with HIF for Asn hydroxylation.
To address these questions, and to determine whether Asn hydroxylation might occur on ARD proteins not captured in previous screens, we chose to study a bioinformaticallyidentified candidate substrate, myosin phosphatase targeting subunit 1 (MYPT1). MYPT1 is an ARD-containing protein with established functions in contractile regulation that are of potential interest to hypoxia biology [12] , and for which there is structural information that might guide analysis of functional effects [13] .
We show that the ARD of MYPT1 contains three sites of asparaginyl hydroxylation, and that these hydroxylations are FIH-dependent. For the first time we show that Asn hydroxylation occurs in an ARD protein purified from an animal: this hydroxylation is incomplete, suggesting that previous results from tissue culture cells give a true reflection of ARD hydroxylation in vivo. Further, we show that MYPT1, and other ARD substrates of FIH, can modulate the transcriptional activity of HIF-CAD through competitive FIH inhibition.
Materials and methods

Cell culture
293T, HeLa and MCF7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) foetal calf serum, 2 mM L-glutamine, 50 IU (international units) ml -1 penicillin and 50 µg ml -1 streptomycin.
Plasmids
Human MYPT1 ARD (residues 1 -296) was amplified by PCR and cloned into pEF1/V5-His A (Invitrogen). Wild-type FIH and D201A FIH plasmids were as described previously [6] . For reporter gene assays, full-length human MYPT1, human MYPT1 ARD (residues 1 -296), mouse Notch1 intracellular domain (ICD, residues 1751 -2531), full-length human Tankyrase1, full-length human p105, full-length human IκBα, full-length human Rabankyrin5 and full-length human RNaseL were amplified by PCR and cloned into p3xFLAG-CMV-10 (Sigma). The integrity of all constructs was verified by DNA sequence determination.
Transfection and reporter gene assays
Cells were transfected in dishes of 10 cm or 15 cm diameter, using 4.5 µg or 10 µg total plasmid DNA respectively and FuGENE® 6 transfection reagent (Roche Applied Science) according to the manufacturer's instructions. Where applicable, MYPT1, ARD, and FIH expression plasmids were co-transfected in a 4:1 ratio. The transcriptional activity of HIF1α CAD was analysed in HeLa cells using a Gal4DBD-HIF-CAD fusion protein and UASluciferase reporter system as described previously [6] .
Knock-down of FIH expression using siRNA
Human FIH (target F1) and control Drosophila HIF (dHIF) duplexes have been described previously [14] , and were synthesized by Ambion. Cells were transfected twice at 24 h intervals using a 20 nM dose of duplex and Oligofectamine reagent (Invitrogen), according to the manufacturer's instructions.
Antibodies
Anti-FIH antibody was as described previously [14] . Anti-MLC (M4401), anti-β-tubulin (T5293) and anti-FLAG M2 peroxidase (A8592) antibodies were from Sigma. Anti-phospho-MLC antibodies (Ser-19 and Ser-19/Thr-18) were from Cell Signaling (3671 and 3674 respectively). Anti-PPIcδ was from Abcam (ab53315). Anti-MYPT1 antibody, F38, was as described [15] .
Immunoprecipitation and immunoblotting
Cells were lysed in Jie's buffer [NaCl 100 mM, TrisHCl pH 7.5 20 mM, MgCl 2 5 mM, Nonidet P-40 0.5% (v/v)] supplemented with Complete, EDTA-free protease inhibitor cocktail (Roche Applied Science). V5-tagged MYPT1 ARD was immunoprecipitated with anti-V5 agarose affinity gel (Sigma). Endogenous MYPT1 was immunoprecipitated by pre-incubation with anti-MYPT1 antibody followed by incubation with protein A agarose (Upstate Biotechnology). For immunoblotting of phospho-MLC, cells were lysed directly into 3x SDS sample buffer and sonicated briefly. Lysates or immunoprecipitates were resolved by SDS-PAGE, electroblotted onto PVDF membranes (Millipore) and probed using the indicated primary antibodies. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (Dako) were used with either SuperSignal West Pico or SuperSignal West Dura (Pierce Biotechnology) to visualize immunoreactive species. Where necessary when immunoblotting immunoprecipitates, anti-rabbit TrueBlot horseradish peroxidase-conjugated secondary antibody (eBioscience) was used to avoid signal from immunoprecipitating immunoglobulin.
Protein digestion and liquid chromatography-MS analysis
After resolution by SDS-PAGE and staining, protein-containing bands were excised and digested in bicarbonate buffer using either sequencing grade trypsin (Promega) or sequencing grade endoproteinase GluC (Roche Applied Science) as described [16] . Liquid chromatography was performed using an Ultimate system equipped with a Famos autosampler and C18 PepMap column (LC Packings). The chromatography system was connected directly to a UV flow cell (Ultimate) and a 3D high-capacity ion trap mass spectrometer (HCTplus, Bruker Daltonics) via a pneumatically assisted nano-electrospray source. Silica-coated Picotips (New Objective) were used for electrospray ionization.
Instruments were controlled using HyStar 3.0 and EsquireControl 5.2 software (Bruker Daltonics). Raw chromatography data were processed and Mascot-compatible files generated using DataAnalysis 3.2 software (Bruker Daltonics). Searches were performed using Mascot software (Matrix Science [17]) using the most recent releases of the SwissProt or NBCInr databases, following which MS/MS spectra and extracted ion chromatograms were analysed in detail using DataAnalysis 3.2.
Protein purification
Endogenous myosin phosphatase holoenzyme was purified from turkey gizzard as described [18] .
Statistical analysis
Unless otherwise stated quantitative data are represented as the mean ±S. E. M. of three experiments. Statistical significance was evaluated using Student's t test.
Results
MYPT1 is a potential FIH substrate
FIH-dependent Asn hydroxylation sites within ARDs conform to a L (-8) D/E (-2) XN motif specifically located to the β hairpin loops that connect ARs [5] [6] [7] . Bioinformatic alignment with known FIH substrates ( Figure 1 ) indicated that the targeting subunit of smooth muscle myosin phosphatase, MYPT1, contains two potential hydroxylation sites within the β-hairpin loops of its ARD that match the L (-8) D/E (-2) XN consensus (Asn-67 and Asn-226) and a further two conforming to L (-8) N (Asn-100 and Asn-288). Three of these sites (Asn-67, Asn-100 and Asn-226) have additional similarities to previously identified substrates in the primary sequence ( Figure 1 ).
The ARD of MYPT1 is hydroxylated in vivo
To determine if any of the identified Asn residues were hydroxylated in vivo we immunopurified V5-tagged human MYPT1 ARD from transfected 293T cells. The purified ARD protein was resolved by SDS-PAGE and digested using either trypsin or endoproteinase GluC before analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Peptides containing all four candidate asparagine residues were observed, and MS/MS sequencing assigned hydroxylation at Asn-67, Asn-100 and Asn-226 (Figures 2 and S1 ). No hydroxylation was detected at Asn-288 (data not shown), the site with the least similarity to known FIH substrates ( Figure 1 ).
FIH is necessary and sufficient for hydroxylation of the MYPT1 ARD
In order to determine whether MYPT1 was a substrate for FIH we quantified hydroxylation at Asn-67, Asn-100 and Asn-226 by liquid chromatography-mass spectrometry (LC-MS) under conditions of various FIH interventions. 293T cells were transfected with small interfering RNA (siRNA) duplexes targeting FIH or a control sequence (dHIF), then subsequently transfected with MYPT1 ARD plus pcDNA3 vector (EV), FIH or a hydroxylation-defective FIH mutant (D201A). After immunoprecipitation and digestion, the extent of hydroxylation at each site was determined by LC-MS. In the presence of endogenous levels of FIH each of the three sites was around 5 -10% hydroxylated at the target Asn ( Figure 3A) . Overexpression of FIH increased the level of hydroxylation to approximately 90% whilst overexpression of the FIH D201A mutant had no effect. Suppression of FIH by siRNA reduced the extent of hydroxylation at all three sites. Although consistent across the three sites this effect of FIH suppression was not statistically significant. This is likely to reflect the low basal levels of MYPT1 hydroxylation present under the experimental conditions, which were approaching the limits of detection by mass spectrometry, combined with the incomplete siRNA-mediated suppression of FIH ( Figure 3B ).
These results thus confirm bioinformatic predictions that MYPT1 contains multiple sites of FIH-dependent hydroxylation within its ARD, consistent with the hypothesis that FIH-mediated hydroxylation is a general phenomenon among ARD-containing proteins. They also indicate that, at least in transfected tissue culture cells, hydroxylation of individual ARs is incomplete.
Endogenous MYPT1 is hydroxylated
To test whether Asn hydroxylation occurs in the full length protein in vivo, and to assess the extent of hydroxylation in normal tissue, we next sought to determine whether a sample of endogenous animal MYPT1 was hydroxylated. A sample of myosin phosphatase holoenzyme, purified from turkey gizzard, was resolved by SDS-PAGE and stained with Coomassie blue. The MYPT1 species was excised and digested with trypsin or GluC, then analysed by LC-MS/MS and LC-MS.
Although the turkey MYPT1 gene has not been sequenced, the amino acid sequence of the chicken protein is available (NCBInr database, gi number 633038). As conservation of the MYPT1 ARD between human and chicken is greater than 96%, it seems reasonable to assume a high degree of conservation between the chicken and turkey sequences. Searching the MS/MS fragmentation data against the chicken protein sequence correctly identified many predicted peptides, validating this assumption. MS/MS sequencing confirmed hydroxylation at Asn-67 and Asn-100 ( Figure S2 ), and LC-MS quantified the degree of hydroxylation at the Asn-67 and Asn-100 sites as 48% and 43%, respectively (Figure 4) . A peptide containing Asn-288 was observed by GluC digestion, but in agreement with the data from cell culture experiments no hydroxylation was detected at this site (data not shown). A peptide containing Asn-226 was not detected in these experiments, likely due to a Gly to Arg substitution four residues N-terminal to Asn-226 in the chicken protein relative to human MYPT1, which results in a short tryptic fragment that is not amenable to detection by MS.
FIH does not affect the interaction between MYPT1 and PPIcδ nor MLC phosphorylation
We next sought to understand what the consequences of Asn-hydroxylation are on the function of myosin phosphatase. MYPT1 regulates myosin light chain (MLC) phosphorylation by recruiting the protein phosphatase type 1c δ isoform (PP1cδ), by imparting selectivity towards MLC and by fully activating the myosin phosphatase complex [19] .
The structure of the N-terminus of MYPT1 in complex with PP1cδ shows that the main binding site for PP1cδ is the well-characterized PP1 binding motif (KVKF) located immediately Nterminal to AR1 [13] . Additional interactions are mediated by the ARD: the β-hairpin loops of the two groups of ARs form a 'clamp' that stabilizes the C-terminal tail of PP1cδ ( Figure S3 ). Several residues in the MYPT1 ARD interact with PP1cδ, including Val-71 which is adjacent to Asn-67, and Asp-229 and Trp-231 which are C-terminal to Asn-226: this raises the possibility that hydroxylation of the Asn residues could modulate the interaction with PP1cδ. To test this we immunoprecipitated endogenous MYPT1 from 293T cells transfected with pcDNA3 vector (EV), FIH, D201A FIH, control siRNA (dHIF) or FIH siRNA. Small amounts of overexpressed FIH were observed co-immunoprecipitating with endogenous MYPT1. However, neither FIH overexpression nor knock-down affected the interaction between MYPT1 and PP1cδ ( Figure 5A ).
Structural data indicate that binding of phosphorylated MLC to the myosin phosphatase holoenzyme is mediated by an acidic groove created by the catalytic cleft of PP1cδ and the α-helices of the MYPT1 ARs [13] . It is thought that this interaction promotes the activity and specificity of PP1cδ for phosphorylated MLC. To determine whether FIH-mediated MYPT1 ARD hydroxylation regulates PP1cδ activity towards phosphorylated MLC we asked whether FIH overexpression or knock-down had any effect on MLC phosphorylation using antibodies specific for phosphorylated MLC (Ser-19 or Thr-18/Ser-19). FIH knock-down or overexpression did not alter the levels of phosphorylated MLC in 293T, HeLa or MCF7 cells, nor did they significantly affect the level of MYPT1 ( Figure 5B ).
Therefore, FIH-mediated Asn hydroxylation does not appear to affect the function of myosin phosphatase dramatically, at least under the conditions tested.
MYPT1 and other ARD-containing proteins can influence HIF transcriptional activity through competition for FIH
We have previously shown that Notch1 overexpression competitively inhibits HIF-CAD hydroxylation [6] . This competition results in enhanced HIF-CAD activity that can be detected in a luciferase reporter assay based on UAS Luciferase and a HIF-CAD-GAL4 DNA binding domain (GAL4 DBD) fusion. To test whether MYPT1 also enhances HIF-CAD activity, and whether this property is observed more generally among ARD substrates of FIH, HeLa cells were transfected with HIF-CAD:GAL4 DBD, UAS luciferase and 3xFLAG-tagged ARDcontaining proteins. As expected, extracts from cells transfected with Notch1 ICD displayed luciferase activity five to six-fold higher than control samples expressing only HIF-CAD:GAL4 DBD and UAS Luciferase, reflecting reduction in FIH-mediated suppression of HIF-CAD activity by Notch1 ( Figure 6A ). Consistent with competitive inhibition of HIF-CAD hydroxylation, full-length MYPT1 and MYPT1 ARD also greatly enhanced HIF-CAD activity (six to seven-fold increase in luciferase activity), with a smaller effect (three-fold increase in luciferase activity) observed for RNaseL. Tankyrase1 (a novel ARD FIH substrate -Matthew E Cockman, personal communication) and IκBα showed a small but significant effect on HIF-CAD activity in this assay whereas p105 and Rabankyrin5 did not. When expressed at maximal plasmid doses, Rabankyrin5 and IκBα elicited much greater fold increases in luciferase activity, in contrast to p105 and Tankyrase1 which did not (data not shown). These data therefore suggest that many, but not all, ARD FIH substrates have the potential to inhibit
Discussion
We show here that the targeting subunit of the smooth muscle myosin phosphatase holoenzyme, MYPT1, is a novel FIH substrate and that its ARD is targeted for Asn hydroxylation at multiple independent sites. The initial candidacy of these sites was based on bioinformatic alignment with known FIH substrates. Similar analysis suggests that most ARD proteins contain at least one candidate FIH hydroxylation site that fulfils the dual requirements of conforming to the consensus and being located on the β-hairpin loop of the AR. We therefore infer that the hydroxylation of ARDs by FIH is likely to be common, though perhaps not universal.
Of the four predicted hydroxylation sites in the eight ARs of the MYPT1 ARD, only Asn-288 was shown not to be an FIH substrate. It is unclear at present whether this is due to the divergent sequence surrounding Asn-288 relative to other FIH substrates (Figure 1 ), or to the fact that AR8 does not adopt a canonical AR fold [13] . Interestingly, Asn-100 was hydroxylated at a similar level to Asn-67 and Asn-226, despite the absence of D/E in the previously described L (-8) D/E (-2) XN motif, showing that an acidic residue is not essential for hydroxylation at this position in all ARD substrates. Taken together the results presented here provide some insight into the primary sequence determinants that regulate FIH-mediated ARD hydroxylation, and suggest that structural factors may also contribute.
Despite the proximity of known interaction sites between MYPT1 and PP1cδ to two of the three Asn hydroxylation sites characterized here, we did not observe any significant effect of FIH manipulation on the MYPT1:PP1cδ interaction, nor on the activity of myosin phosphatase towards MLC. With respect to the MYPT1:PP1cδ interaction this may be unsurprising since the high affinity binding site is located N-terminal to the ARD [20] [21] [22] . Furthermore, Asn-67 and Asn-226 project away from PP1cδ ( Figure 5A ) and may therefore not be expected to modify the described interactions, despite their close proximity [13] . Likewise, the β-hairpin loops, which contain the hydroxylated Asn residues, are located on the opposite face of the ARD from that which contributes to the acidic groove of the MLC binding site, consistent with the absence of detectable regulation of MLC phosphorylation by FIH. Although the lack of effect of Asn hydroxylation on MYPT1 signalling is consistent with similar findings for other ARD substrates, including IκBα and Notch [5, 6] , it is possible that FIH regulates myosin phosphatase under other specific conditions.
One physical consequence of Notch1 ARD Asn hydroxylation is the formation of a hydrogen bond between the newly-created hydroxyl group and an acceptor residue two positions Nterminal to the target Asn [6] . In all previously characterized FIH substrates the predicted acceptor group is the carboxylate of an Asp residue [5] [6] [7] . However, most candidate FIH sites without the D/E of the L (-8) D/E (-2) XN motif still contain a residue capable of hydrogen bonding at this position, including for example the L (-8) N (-2) I (-1) N motif of Asn-100 in MYPT1, suggesting that this may be a general property of FIH-mediated ARD hydroxylation. Analyses of the published MYPT1 ARD structure [13] suggest that all three FIH hydroxylation sites are predicted to create a hydrogen bond to the -2 residue ( Figure S4 ). Studies on a synthetic ankyrin-repeat protein have shown that asparaginyl hydroxylation can stabilize the ARD fold [23] . However, whether the three hydroxylated residues in MYPT1 act in synergy to increase the stability of the canonical ARD fold remains to be determined.
In contrast to IκBα and Notch1, which contain two target Asn residues that are differentially hydroxylated [5, 6] , the three sites of MYPT1 are hydroxylated to approximately the same extent. Although in 293T cells hydroxylation of the overexpressed MYPT1 ARD was at a relatively modest level (5 -10%), this is likely due to saturation of the endogenous FIH: coexpression of exogenous FIH increased hydroxylation at all three sites essentially to completion. In support of this argument, hydroxylation of the two sites observed in endogenous MYPT1 purified from animal tissue was significantly higher than in the overexpressed ARD from tissue culture cells. Importantly however, hydroxylation at these residues was still incomplete. This is consistent with observations made on ARD proteins purified from tissue culture cells [5, 6] , and indicates that incomplete hydroxylation of ARDs is likely to be the physiological norm. This could reflect the fact that endogenous FIH is also limiting in vivo, perhaps due to the ubiquity and abundance of its substrates.
Finally, we demonstrate that, similar to Notch, MYPT1 effectively inhibits FIH-dependent suppression of HIF-CAD activity. Interestingly, overexpression of several other known ARD substrates of FIH also enhanced the activity of HIF-CAD, although this effect is not universal and different ARD substrates compete to different extents ( Figure 6 ). It is possible that the ability of an ARD to promote HIF-CAD activity depends on its affinity for FIH, and therefore on the extent to which the ARD physically sequesters FIH away from HIF-CAD.
Given that FIH-mediated hydroxylation is likely to be very common among ARD proteins, and that several ARD substrates apparently inhibit HIF-CAD hydroxylation, it seems plausible that collectively ARDs act as a "sink" for FIH. This would explain not only the observations of limiting FIH activity towards HIF-CAD in tissue culture models [14] but also the incomplete hydroxylation of ARDs themselves, due to cross-competition. 
Figure 6
MYPT1 and other ARD-containing proteins can influence HIF transcriptional activity through competition for FIH (A) HeLa cells were transfected with UAS Luciferase, HIF-CAD-GAL DBD, the indicated 3xFLAG-tagged ARD protein (mN1 ICD: mouse Notch1 intracellular domain; TNKS1: Tankyrase1) and β-galactosidase as a transfection control. 48 h post-transfection, cells were harvested and analysed in triplicate for luciferase and β-galactosidase activity. ** denotes p < 0.01 relative to EV control sample.
